MarginsXMarginsX
Home › Data Desk › Starling Oncology Inc.: Form 25-NSE filed to end a listing

MarginsX Data Desk · Delistings · Oncology · Debt financing

Starling Oncology Inc.: Form 25-NSE filed to end a listing

On Nov 13, 2026 a Form 25-NSE was filed to take a class of Starling Oncology Inc. (STLN) securities off an exchange. (SEC EDGAR, 25-NSE, Nov 13, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.

Line chart of Starling Oncology Inc. (STLN) daily closes from Jul 6, 2026 to Nov 12, 2026, with the delisting notice on Nov 13, 2026 marked.

The stock

The Nasdaq screener puts its market value at $357.0M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/STLN)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameStarling Oncology Inc.Source2026-11-13
Form25-NSESource2026-11-13
FiledNov 13, 2026Source2026-11-13
WhoStarling Oncology Inc. (STLN)Source2026-11-13
SymbolSTLNSource2026-11-13
Cap356,968,584 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS